Atomo Diagnostics is a pioneering global medical technology company that specializes in user-centered design of innovative rapid diagnostic testing solutions. Based in Sydney, Australia, with international offices, the company is transforming the diagnostics landscape by creating intuitive, accurate, and reliable testing platforms that prioritize ease of use and performance.
The company’s core innovation lies in its AtomoRapid™ diagnostic platforms, which include multiple models like Pascal, Curie, Galileo, Elion, and Florey. These platforms are designed to address common user errors and improve testing experiences across various medical fields, with a particular focus on sexual health, such as HIV self-testing. By integrating advanced design principles, Atomo has achieved significant improvements in diagnostic testing, including a 90% reduction in blood delivery errors and a 40% reduction in procedure time.
Atomo Diagnostics has gained global recognition through strategic partnerships, regulatory approvals, and a commitment to decentralized testing. The company has secured key certifications like WHO Prequalification, FDA 510(k) Clearance, and CE Marking, and has sold platforms in over 40 countries. Their approach goes beyond traditional diagnostics, empowering users with reliable, user-friendly testing solutions that provide greater control and accessibility in healthcare, ultimately driving innovation in point-of-care and self-testing technologies.
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X does not hold an Australian Financial Services Licence (AFSL) and relies on the exemption available under section 911A(2)(eb) of the Corporations Act 2001 (Cth) in respect of any financial product advice provided.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
